The National Times - Frenchman rewarded for lifetime of research into narcolepsy

Frenchman rewarded for lifetime of research into narcolepsy


Frenchman rewarded for lifetime of research into narcolepsy
Frenchman rewarded for lifetime of research into narcolepsy / Photo: © AFP

Emmanuel Mignot is one of the world's leading experts on narcolepsy, a sleep disorder that he finds both "strange" and "fascinating."

Change text size:

The French-born Mignot has dedicated his life to studying the causes of narcolepsy and shedding light on one of the great biological mysteries -- sleep.

His discovery of the genetic and molecular causes of the disorder led to his receiving a prestigious Breakthrough Prize on Thursday along with Japan's Masashi Yanagisawa, who made related findings around the same time.

Because of their discoveries, new treatments for narcolepsy -- which causes people to suddenly fall asleep -- and other sleep disorders are being developed.

About one in every 2,000 people suffers from narcolepsy. Some may experience catalepsy -- a sudden trance-like state.

"I am quite proud because what I have discovered is making an enormous difference for my patients," Mignot said in a telephone interview with AFP. "It's the best reward that one could receive."

The 63-year-old Mignot is a sleep researcher at Stanford University in California.

Thirty years ago, when he was a medical student, Mignot fulfilled his military service requirements in France by coming to Stanford to study a French-made drug that was being used to treat narcolepsy.

At the time, he said, the disease was "virtually unknown" and no one was actively studying it.

He became "completely fascinated."

"I told myself it's incredible, this disease, people fall asleep all the time, we have no idea why, and if we could discover the cause we might understand something new about sleep."

Stanford was already home to a renowned sleep center and its laboratory housed narcoleptic dogs, which Mignot began studying in an effort to find a genetic cause of the disease.

Genome sequencing was very primitive at that time and "everybody told me I was crazy," said Mignot, who currently has an adopted narcoleptic dog called Watson.

"I thought it would take a few years and it ended up taking 10."

In 1999, Mignot found a mutation in the genome of narcoleptic dogs. It was located on membrane receptors in the brain that respond to molecules outside the cell, similar to a lock and a key.

- 'Remake a key' -

The Japanese scientist Yanagisawa, meanwhile, had been studying orphan receptors -- receptors of unknown function -- in mice.

He discovered that a molecule that he named orexin binds to the same receptor Mignot detected as abnormal in dogs.

Mice who were deprived of orexin developed narcolepsy.

Mignot immediately began research on human subjects and found that orexin levels in the brain of narcolepsy patients were zero.

Normally, the molecule is produced in great quantities during the day, especially in the evening, allowing one to fight fatigue.

"You don't make a discovery like this twice in your life," Mignot said. "We found the cause of a disease.

"The advantage, is that we can remake a key," he said, referring to orexin.

For the moment, most patients are treated with a combination of powerful sedatives to help them sleep more soundly and amphetamines to keep them awake during the day.

Mignot said tests using a drug that mimics orexin have been "really miraculous."

Patients are fully awake and "transformed."

The challenge is to develop the right dose to be delivered at the right time.

Several companies, including Takeda of Japan, are working on it, and drugs could be authorized in the next few years.

They could be applied to other patients -- people suffering from depression, for example -- who have difficulty waking up, or to those in a coma.

Mignot meanwhile is studying whether narcolepsy may be caused by a flu virus.

The body's immune system may be confusing a flu virus with the cells that produce orexin and T-cells that fight infection are attacking them as a result.

"I've become interested in how the immune system works in the brain," a field he said is "beginning to explode."

As for sleep, Mignot remains fascinated by it even if he has uncovered one of the great mysteries.

"What is it that sleep does that it is so important that we have to do it every day?" he asked. "It's true that we still don't know."

C.Blake--TNT

Featured

Yesim Travel eSIMs Offer Alternative to Traditional Roaming Charges

Swiss telecommunications provider Yesim is positioning its travel eSIM services as a cost-effective alternative to conventional mobile roaming. With over four million users globally, the company offers digital plans designed to eliminate daily data caps and unpredictable charges for travelers in more than 200 destinations.

Samsung Galaxy S27 Series Camera Design Leaked via Lens Protectors

Images of camera lens protectors for the upcoming Samsung Galaxy S27 series have surfaced, offering new details about the flagship phones' rear design. The leak suggests that while the standard Galaxy S27 and S27+ will keep a vertical triple-camera layout, the Pro and Ultra models may adopt a distinct configuration with separate openings for the main and ultrawide sensors.

Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power

AI, scalability and channel empowerment lead the conversations at this year's executive event

Archive of Our Own Restores Service After Weeks-Long Security Shutdown

The Archive of Our Own (AO3) has resumed operations after a 17-day shutdown caused by an unspecified security breach. The Organization for Transformative Works announced the restoration on November 15, noting that while user data likely remains secure, certain site functionalities are temporarily limited to manage high traffic and expedite the return to full service.

Change text size: